Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 known ✓ | P23458 | 12/20 | 0.58 |
| ▸ | MAPK14 known ✓ | Q16539 | 1/20 | 0.50 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.44 |
| ▸ | JAK2 known ✓ | O60674 | 10/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | PAK4 | O96013 | 2/20 | 0.50 |
| ▸ | PRKX | P51817 | 2/20 | 0.50 |
| ▸ | GSK3A | P49840 | 2/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.49 |
| ▸ | MARK3 | P27448 | 1/20 | 0.47 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 10/20 | 0.40 |
| ▸ | TYK2 | P29597 | 9/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | GPX4 | P36969 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715014 | 0.77 | MAP4K4 (0.58) | KDM4EALDH1A1TP53HPGDHSD17B10 | |
| SCHEMBL1803254 | 0.76 | JAK1 (0.60) | KDM4EALDH1A1TP53HPGDHSD17B10 | |
| SCHEMBL1801293 | 0.74 | KDM4E (0.39) | KDM4EALDH1A1TP53HPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL4715431 | 0.67 | JAK1 (0.63) | KDM4EALDH1A1TP53HPGDHSD17B10 | |
| SCHEMBL4716805 | 0.61 | KDM4E (0.43) | KDM4EALDH1A1HPGDHSD17B10JAK1 | |
| SCHEMBL1802992 | 0.58 | HPGD (0.73) | KDM4EALDH1A1TP53HPGDHSD17B10 | |
| SCHEMBL5444622 | 0.57 | JAK1 (0.49) | KDM4EALDH1A1TP53HPGDHSD17B10 | |
| SCHEMBL12931049 | 0.55 | JAK1 (0.46) | KDM4EALDH1A1TP53HPGDHSD17B10 | |
| SCHEMBL3184818 | 0.54 | KDM4E (0.49) | KDM4EALDH1A1HPGDHSD17B10JAK1 | |
| SCHEMBL8404400 | 0.54 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641454-B1 | PYRAZOLO[3,4-B]PYRIDIN-6-ONES AS GSK-3 INHIBITORS | PFIZER PROD INC (US) | 2008-10-01 | — | — | EP | disclosed |
| EP-1641455-B1 | PYRAZOLO[3,4-B]PYRIDIN-6-ONES AS GSK-3 INHIBITORS | PFIZER PROD INC (US) | 2008-08-06 | — | — | EP | disclosed |
| US-7300943-B2 | GSK-3 inhibitors | PFIZER INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300944-B2 | Pyrazolo[3,4-b]pyridin-6-ones as GSK-3 inhibitors | PFIZER INC. (US) | 2007-11-27 | — | — | US | disclosed |
| EP-1641455-A1 | PYRAZOLO[3,4-B]PYRIDIN-6-ONES AS GSK-3 INHIBITORS | Pfizer Products Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050026946-A1 | GSK-3 inhibitors | PFIZER INC | 2005-02-03 | — | — | US | disclosed |
| WO-2005000304-A1 | PYRAZOLO[3,4-B]PYRIDIN-6-ONES AS GSK-3 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040266815-A1 | Pyrazolo[3,4-b]pyridin-6-ones as GSK-3 inhibitors | PFIZER INC | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026946-A1 | GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | JAK1 334/4885MAPK14 1992/4885RET 525/4885 |
| US-20040266815-A1 | Pyrazolo[3,4-b]pyridin-6-ones as GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | JAK1 280/4885MAPK14 1288/4885RET 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.